C07D273/01

Matrix Metalloproteinase Inhibitors and Imaging Agents, And Methods Using Same

The present invention provides certain compounds, Formula (I), or salts or solvates thereof, which can be used as matrix metalloproteinase-targeted inhibitors or imaging agents.

##STR00001##

PHOTO-COUPLED SYNERGISTICALLY CROSSLINKED HYDROGEL MATERIAL AND ITS COMPOSITION, PREPARATION METHOD, USE, PRODUCT, AND PREPARATION KIT

This invention provides a preparation, composition, product, and application of a photo-coupled synergistically crosslinked hydrogel material. The preparation includes dissolving Component A including a photosensitive polymer derivative having o-nitrobenzyl phototriggers and Component B including a polymer derivative having amine or alkene (double group) or sulfhydryl group in a biocompatible medium to obtain solution A and solution B, respectively; mixing the solution A and solution B homogeneously to obtain a hydrogel precursor solution; initiating photo-coupled synergistic crosslinking under an irradiation of a UV light to form the hydrogel. The irradiation causes the o-nitrobenzyl phototriggers to generate an aldehyde group/keto group or a nitroso group to initiate photo-coupled synergetic crosslinking. The photo-coupled synergistically crosslinked hydrogel has applications in tissue engineering, regenerative medicine, 3D printing and as a carrier of cell, protein or drug.

PHOTO-COUPLED SYNERGISTICALLY CROSSLINKED HYDROGEL MATERIAL AND ITS COMPOSITION, PREPARATION METHOD, USE, PRODUCT, AND PREPARATION KIT

This invention provides a preparation, composition, product, and application of a photo-coupled synergistically crosslinked hydrogel material. The preparation includes dissolving Component A including a photosensitive polymer derivative having o-nitrobenzyl phototriggers and Component B including a polymer derivative having amine or alkene (double group) or sulfhydryl group in a biocompatible medium to obtain solution A and solution B, respectively; mixing the solution A and solution B homogeneously to obtain a hydrogel precursor solution; initiating photo-coupled synergistic crosslinking under an irradiation of a UV light to form the hydrogel. The irradiation causes the o-nitrobenzyl phototriggers to generate an aldehyde group/keto group or a nitroso group to initiate photo-coupled synergetic crosslinking. The photo-coupled synergistically crosslinked hydrogel has applications in tissue engineering, regenerative medicine, 3D printing and as a carrier of cell, protein or drug.

SSAO INHIBITORS AND USES THEREOF

Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.

Method for producing kakeromycin and derivatives thereof

Provided is a production method of kakeromycin and a derivative thereof showing an antifungal activity and cytotoxicity and expected as a new antifungal agent or anticancer agent, by chemical synthesis. A production method of a compound represented by the formula (1): ##STR00001##
wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; and n is 0 or 1, or a salt thereof, including a step of subjecting a compound represented by the formula (2): ##STR00002##
wherein R and n are as defined above, or a salt thereof, to an oxidation reaction.

ELECTROLYTE-ADDITIVE FOR LITHIUM-ION BATTERY SYSTEMS

The invention relates to the use of compounds according to general formula (1), in particular 1,4,2-dioxoazol-5-on-derivatives, as additives in electrolytes for electrochemical energy sources such as lithium-ion-batteries, and compounds containing electrolytes according to general formula (1), in particular, 1,4,2-dioxoazol-5-on-derivatives.

ELECTROLYTE-ADDITIVE FOR LITHIUM-ION BATTERY SYSTEMS

The invention relates to the use of compounds according to general formula (1), in particular 1,4,2-dioxoazol-5-on-derivatives, as additives in electrolytes for electrochemical energy sources such as lithium-ion-batteries, and compounds containing electrolytes according to general formula (1), in particular, 1,4,2-dioxoazol-5-on-derivatives.

Nrf2 REGULATORS

The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

Nrf2 REGULATORS

The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

Heterocyclic GLP-1 agonists

This disclosure relates to GLP-1 agonists of Formula I: ##STR00001##
including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.